|
Post by sportsrancho on Feb 15, 2017 8:55:30 GMT -5
If this is indeed launch 3.0 with MNKD sales reps hitting the streets tomorrow, how soon before we see a nice rise in script numbers? My guess is it will be at least 6 weeks... 80 reps making 6 calls per day minimum, or 480 calls per day will have an effect. Likely not as fast as we want, but very soon. I agree, it shouldn't be that hard to get what we were doing with SNY. ( 600-700 ) The doc's that were writing scripts will start back up now that they know we are still up and running. Then the ads need to kick in.
|
|
|
Post by thekid2499 on Feb 15, 2017 18:08:54 GMT -5
It really is shocking to me how little has been done at this point to market Afrezza and raise awareness. I have a family member who is in the health care system in the Northeast and manages various practices. Today is literally the first time someone has come in to introduce one of his practices to Afrezza. The physicians literally have never heard of it before. The questions the physicians were asking (about spirometry and cancer concerns) are issues that were being discussed 2 years ago here. While the physicians came away impressed and are going to try Afrezza on a few targeted patients, it is crazy to me that this is the first time they have been exposed to Afrezza. The person who gave the presentation from MNKD was the regional sales manager because according to him, his team hasn't been fully built out yet.
|
|
|
Post by sportsrancho on Feb 15, 2017 18:13:39 GMT -5
It really is shocking to me how little has been done at this point to market Afrezza and raise awareness. I have a family member who is in the health care system in the Northeast and manages various practices. Today is literally the first time someone has come in to introduce one of his practices to Afrezza. The physicians literally have never heard of it before. The questions the physicians were asking (about spirometry and cancer concerns) are issues that were being discussed 2 years ago here. While the physicians came away impressed and are going to try Afrezza on a few targeted patients, it is crazy to me that this is the first time they have been exposed to Afrezza. The person who gave the presentation from MNKD was the regional sales manager because according to him, his team hasn't been fully built out yet. Wow! I agree with your post! But it is so good to hear that something is being accomplished!! Thank you:-)
|
|
|
Post by tarheelblue004 on Feb 15, 2017 18:21:15 GMT -5
really good news from where I'm standing! i'm not one to look backwards - this type of progress, while a long time coming, is in my mind really good news...thanks for the update thekid2499.
|
|
|
Post by sportsrancho on Feb 15, 2017 19:49:17 GMT -5
I'm excited! Remember we have 80-100 reps out in the field doing the same thing! I was told they would start this week and they have. It's like we have a new drug no one has heard about. This is the beginning ...the docs that push it aside will be left behind. Thank you sales team!
|
|
|
Post by mnholdem on Feb 15, 2017 20:02:20 GMT -5
After hearing that MannKind has cancelled presentations of Afrezza to interested physicians, this is welcome news.
|
|
|
Post by thekid2499 on Feb 16, 2017 16:19:19 GMT -5
I wanted to provide a bit more information that has been provided to me regarding my original post. The regional sales manager visited another of the practices that my family member helps run today. While the first practice had one endo embedded in a group of physicians, this practice was solely made up of endos. Though obviously a small sample, I'm hopeful (optimistic even)that a concerted effort is finally being made now that we have our own sales team. One question asked by one of the endos was "Is Afrezza weight neutral"? The sales manager was not able to answer the question and said he would have to get back to the endo on that particular question.
|
|
|
Post by falconquest on Feb 16, 2017 16:26:36 GMT -5
I wanted to provide a bit more information that has been provided to me regarding my original post. The regional sales manager visited another of the practices that my family member helps run today. While the first practice had one endo embedded in a group of physicians, this practice was solely made up of endos. Though obviously a small sample, I'm hopeful (optimistic even)that a concerted effort is finally being made now that we have our own sales team. One question asked by one of the endos was "Is Afrezza weight neutral"? The sales manager was not able to answer the question and said he would have to get back to the endo on that particular question. I am in sales. The answer is, "Of course it is, does anyone else have any questions?"
|
|
|
Post by sportsrancho on Feb 16, 2017 18:17:00 GMT -5
|
|
|
Post by compound26 on Feb 16, 2017 18:30:02 GMT -5
I wish our sales people are more familiar with the trial data. The weight gain/loss issue is one of the benefits of Afrezza (especially if we are talking about type ones) that we can probably present to the doctors (by referring them to the trial data) and the data is right there. Pages 85 and 89 of the Afrezza FDA briefing documents: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390864.pdfBody Weight – Study 171 At Week 24, subjects in the Afrezza TI Gen2 group had a weight loss (mean change from
Baseline -0.39 kg), whereas subjects in the insulin aspart group had a weight gain (mean change
from Baseline 0.93 kg; p = 0.0079) with the resulting difference between treatment groups in change from Baseline favoring the Afrezza TI Gen2 group (-1.32 kg; 95% CI -2.33 to -0.31 kg; p = 0.0102). Reviewer’s comment: Analysis of body weight is difficult to interpret in light of the difference in efficacy between Afrezza TI and insulin aspart seen in the trial. Body Weight – Study 175 In the Sponsor’s analysis, from baseline to Week 24, subjects’ mean body weight increased 0.49
kg in the Afrezza TI Gen2 group and decreased 1.13 kg in the placebo group, with a betweengroup difference of 1.62 kg favoring the placebo group, 95% CI: 0.90 - 2.34; p <0.0001). The FDA statistical reviewer’s analysis showed similar results. Reviewer’s comment: This result is not remarkable given that insulin is known to cause body weight gain. A less effective insulin product would be expected to cause less weight gain.And anecdotal evidence of Afrezza helps weight control is also right there: www.afrezzajustbreathe.com/weigh-loss-on-afrezza/
|
|
|
Post by slugworth008 on Feb 16, 2017 18:38:36 GMT -5
Afrezza may help you lose weight. But owning MNKD has increased my alcohol consumption making weight loss tough for me - lol
|
|
|
Post by falconquest on Feb 16, 2017 19:45:52 GMT -5
Afrezza may help you lose weight. But owning MNKD has increased my alcohol consumption making weight loss tough for me - lol LOL! I'm right there with you slug. What a long strange trip it's been.
|
|
nsmyth
Lab Rat
Posts: 43
Sentiment: Long
|
Post by nsmyth on Feb 16, 2017 20:43:06 GMT -5
Afrezza may help you lose weight. But owning MNKD has increased my alcohol consumption making weight loss tough for me - lol funny, I have been drinking more too since investing in mnkd. (or maybe not funny!)
|
|
|
Post by slugworth008 on Feb 16, 2017 23:07:39 GMT -5
Afrezza may help you lose weight. But owning MNKD has increased my alcohol consumption making weight loss tough for me - lol LOL! I'm right there with you slug. What a long strange trip it's been. Oh hell yes - Too long and way, way too strange.
|
|
|
Post by careful2invest on Feb 17, 2017 0:34:49 GMT -5
LOL! I'm right there with you slug. What a long strange trip it's been. Oh hell yes - Too long and way, way too strange. Slugworth, Switch from beer to bourbon. Takes away the stress, no weght gain! A little ganja newer hurts either...might even be legal depending on where you live! Blend them together and it's nighty night time! GLTA TRUE LONGS!
|
|